Akums Drugs & Pharmaceuticals Ltd.

₹669

-11.2 (-1.6%)

AKUMS Share Price

Pharmaceuticals & Biotechnology

As on October 23, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 10,515.5 Cr

P/E Ratio40.14

Dividend Yield0.22 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	696.85	Bearish
10-DMA	727.66	Bearish
20-DMA	769.5	Bearish
50-DMA	766.99	Bearish
100-DMA	703.96	Bearish
200-DMA	596.04	Bullish

Historical Performance

1 Year

44.5%

3 Years

N/A

5 Years

N/A

10 Years

N/A

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	43,590	41,182	41,782	36,548	36,719
Total Expenditure	38,370	36,575	40,552	33,608	37,636
Other Income	1,287	560	340	901	226
Operating Profit	6,507	5,166	1,570	3,841	-691
Interest	941	346	506	462	167
Depreciation	1,546	1,534	1,256	1,128	947
Profit Before Tax	3,821	3,453	-453	1,503	-1,932
Consolidated Net Profit	2,552	3,382	-40	949	-2,525
Adjusted EPS	17	22	---	7	-18

Compounded Sales Growth

10 Years:21.4

5 Years:9.9

3 Years:3.6

TTM:1.1

Compounded Profit Growth

10 Years:32.9

5 Years:15.8

3 Years:21.9

TTM:-5.5

Stock Price CAGR

10 Years:N/A

5 Years:N/A

3 Years:N/A

TTM:45.3

Return on Equity

10 Years:7.4

5 Years:-17.7

3 Years:-0.3

last year:16.7

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	306	306	286	286	143
Total Reserves	32,827	30,164	6,809	6,886	6,077
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	8,502	-520	14,623	12,461	11,526
Other Current Liabilities	3,453	1,797	2,527	2,462	2,381
Short Term Borrowings	730	137	3,677	3,876	3,379
Total Liabilities	52,761	39,054	33,933	32,350	30,502
Capital Work in Progress	1,767	1,596	1,951	1,030	308
Long Term Loans & Advances	759	614	564	964	861
Currents Investments	---	---	---	---	---
Short Term Loans and Advances	3,035	2,150	1,694	1,393	1,450
Total Current Assets	35,599	22,746	19,408	18,789	18,641
Total Assets	52,761	39,054	33,933	32,350	30,502
Adjusted Book Value	216	199	50	50	43

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 40.14, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a weak 3-year price CAGR of -8.3%, indicating poor shareholder returns.
The stock carries a beta of 0.9, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹6507 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹43590 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 1452611

No. of Shares: 2171 (Approx)

Performance:45.3%

452611

NIFTY Performance: -12.4%

1 day Top Gainers